News

A University of Utah doctor’s research led to a major HIV drug. He worries federal cuts will stop people from getting it.
The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...
FDA approves HIV drug based on University of Utah biochemist’s findings
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.
News Tribune1d
World’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...
Healthline2d
FDA Approves 'Breakthrough' Twice-Yearly Injection to Prevent HIV
The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...
MPR2d
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Metro Weekly3d
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection
He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...
Here’s what everyone should know about this new HIV prevention shot
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.